Merck KGaA agreed to buy SpringWorks Therapeutics Inc., a maker of medicines for cancer and rare diseases, to boost its ...

Akeso Inc. shares plunged as much as 19% in Hong Kong on Monday morning after preliminary data for its new cancer drug fell ...

Patients will likely eventually see higher prices and drug shortages under President Trump's plan to assess tariffs on ...

Merck’s first-quarter net income increased as sales of its Keytruda cancer drug rose, but the Big Pharma company cut its 2025 ...

Pharmaceuticals giant Merck & Company (MRK) has cut its full-year profit forecasts fearing a $200 million hit from President ...

Shares of Merck & Co. Inc. MRK advanced 1.44% to $78.97 Tuesday, on what proved to be an all-around positive trading session ...

We recently published a list of Billionaire Ken Fisher’s 10 Healthcare Stock Picks with Massive Upside Potential. In this ...

Merck is growing pharma sales and expanding margins, led by strong KEYTRUDA performance and cost discipline. Read more about ...

The drugmaker absorbed additional tariff-related costs in the first quarter, but has taken steps to lower the financial ...

We recently published a list of 20 Best Stock To Buy According to Marjorie Taylor Greene. In this article, we are going to ...

Merck KGaA has confirmed that it is in late-stage discussions with SpringWorks, valuing the deal at a price of around $47 per ...